Mechanisms of action of systemic antifungal agents. 1993

B E Elewski
Department of Dermatology, University Hospitals of Cleveland, Ohio 44106.

An understanding of the mechanisms of action and in vitro profiles of antifungal agents is pivotal to selecting effective treatments for dermatophytoses. The principal mechanisms of action of antifungal drugs include disruption of spindle and cytoplasmic microtubule function (e.g., griseofulvin), depletion of or binding to ergosterol (e.g., terbinafine, ketoconazole, and amphotericin B), and accumulation of squalene (terbinafine). It is likely that antifungal agents that deplete or bind to ergosterol have fungistatic activity only; agents that produce a concomitant accumulation of intracellular squalene have fungicidal activity. Although the mechanism of action markedly influences the clinical efficacy of an antifungal agents, in vitro and in vivo antimycotic profiles and bioavailability factors such as drug access to the stratum corneum also contribute to the effectiveness of antifungal agents.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D003881 Dermatomycoses Superficial infections of the skin or its appendages by any of various fungi. Skin Diseases, Fungal,Dermatomycosis,Dermatophyte Infection,Fungal Skin Diseases
D004875 Ergosterol A steroid occurring in FUNGI. Irradiation with ULTRAVIOLET RAYS results in formation of ERGOCALCIFEROL (vitamin D2). Lumisterol,Pro-Vitamin D2,Provitamin D 2,D2, Pro-Vitamin,Pro Vitamin D2
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

B E Elewski
June 2003, Trends in microbiology,
B E Elewski
January 2003, Enfermedades infecciosas y microbiologia clinica,
B E Elewski
July 2001, Indian journal of pediatrics,
B E Elewski
January 1990, Texas Heart Institute journal,
B E Elewski
December 1984, American family physician,
B E Elewski
May 1988, The Medical clinics of North America,
B E Elewski
June 1988, Clinical pharmacy,
B E Elewski
August 1982, Gastroenterology,
B E Elewski
January 1990, Diagnostic microbiology and infectious disease,
Copied contents to your clipboard!